不久前，中国人民银行会同国家发展改革委、金融监管总局联合制定的《人民币现金收付及服务规定》 （以下简称《规定》）正式施行。《规定》直面近年来频发的拒收现金乱象，为流通领域现金使用划定 清晰标准，以制度刚性守护法定货币权威。 中国人民银行法明确规定，中华人民共和国的法定货币是人民币。以人民币支付中华人民共和国境内的 一切公共的和私人的债务，任何单位和个人不得拒收。此次《规定》再次强调，除因履行法律、法规、 规章规定的义务或法定职责而应使用非现金支付工具情形外，不得拒收现金。在数字支付工具出现之 前，人民币现金支付作为最基础的支付形式，在服务实体经济、调节货币流通、应对极端情况等方面发 挥着重要的兜底作用。 随着金融科技发展，现代化、多样化的人民币支付方式已深入我国社会经济生活的各个领域。数据显 示，我国移动支付普及率已达到86%。使用现金的人数、频率和交易金额呈下降趋势，现金支付中的备 付零钱、清点数额、鉴别真伪及保管等问题也日益减少。 在这样的背景下，"只能扫码、不收现金"的情况频频上演。央行公布的2025年第四季度拒收现金行政处 罚情况显示，有商家因拒绝客户使用现金缴纳停车费或办理投保业务而被处以警告、罚款 ...

2026年2月1日，中国人民银行会同国家发展改革委、金融监管总局联合制定的《人民币现金收付及服务 规定》正式施行。新规直面近年来频发的拒收现金乱象，为流通领域现金使用划定清晰标准。 在移动支付成为主流的今天，不少人可能好奇：为何要专门出台政策保护现金支付？答案藏在我们身边 那些被数字浪潮边缘化的群体里。央行抽样调查显示，超过75%的老年人经常使用现金，这一比例在县 域老年人中更是高达80.4%。 数字时代的支付困境 《人民币现金收付及服务规定》2月1日正式施行，为现金支付构建全链条保障体系。新规基于分类管理 和普遍适用原则，提出保障现金支付的基本要求。 人工收款、面对面服务必须支持现金支付。采取人工方式收款、提供面对面服务以及线上预约交易、线 下完成服务或货物交付的场合，收费单位和经营主体应支持现金支付，保持合理的零钱备付。 无人值守场所需公示现金转换方式。采取无人值守、机具设备等自助服务模式，以及采用"一卡通"结算 的场所，应在醒目位置标识现金收取转换方式及服务联系电话，且不得收取额外手续费。 全部交易均通过网络完成的，收费单位应提前公示支付方式，尊重公众知情权和选择权。 "只能扫码、不收现金"的场景遍布餐 ...

此外，《规定》强调，银行业金融机构在客户现金存取、货币兑换、建立现金服务应急保障机制等方面做好服务。其 中提到，银行网点布局应为老年人、残障人士、境外人士提供现金业务办理便利，充分考虑其需求与习惯合理布设现 金自助机具。针对突发情况及特殊群体的现金需求，保障现金供应、优化窗口服务、维护营业网点秩序。 在素喜智研高级研究员苏筱芮看来，人民币现金收付及服务的实施，属于构建健康的多元支付体系的关键环节，主要 意义体现在如下方面：一是巩固"现金"作为金融服务的公共基础与安全底线，明确现金在偏远地区、电力中断、网络 不畅等极端情况下的兜底作用；二是推动支付工具公平协同发展，保障公众的支付选择权，创建公平竞争的市场经营 环境；三是弥合"数字鸿沟"，能够解决老年人、残障人士等群体在支付数字化中遭遇的困境，体现普惠金融的包容 性。 博通咨询首席分析师王蓬博指出，《规定》落地的核心是维护人民币法定地位，同时细化了不同场景的现金收付要求 和金融机构服务标准。新规不是否定非现金支付，而是保障现金正常使用，尤其兼顾老年人等习惯使用现金群体的需 求，让现金和非现金支付互补发展，也让金融服务覆盖更全面。 违规拒收可举报 人民币现金收付领 ...

Group 1 - The core investment theme for the pharmaceutical sector in 2026 is the innovation drug industry chain, with a clear trend towards international business development and accelerated commercialization of domestic products [2][3]. - The CXO sector is experiencing continuous improvement in performance and orders, supported by favorable financing conditions that benefit the industry's upward trajectory [3]. - The medical device sector is focusing on two main lines: international expansion and innovation [3]. Group 2 - The latest trends in medical insurance show a decline in total expenditure for the first ten months of 2025, amounting to 1,903.6 billion yuan, a year-on-year decrease of 1% [5][7]. - The total income of the medical insurance fund for the same period reached 2,352 billion yuan, with a year-on-year growth of 2%, indicating a slowdown in income growth [7][11]. - The number of medical insurance beneficiaries and hospitalization cases continues to grow, with 6.07 billion total beneficiaries in 2024, a year-on-year increase of 18% [11]. Group 3 - The average medical insurance cost per visit decreased in 2024, with the average cost for employees at 629 yuan (down 10%) and for residents at 351 yuan (down 12%) [15]. - The average hospitalization cost also saw a decline, with employees averaging 11,707 yuan (down 3.8%) and residents at 7,408 yuan (down 3.5%) [15]. Group 4 - The Chinese pharmaceutical industry is witnessing a significant increase in license-out transactions, with over 100 deals completed in 2025, totaling more than 110 billion USD [21][32]. - The number of license-out transactions involving upfront payments exceeding 100 million USD has also risen, indicating a growing interest from global pharmaceutical companies in Chinese innovations [21][32]. - The ADC (Antibody-Drug Conjugate) market is expanding rapidly, with a projected market size exceeding 16 billion USD in 2025, driven by several successful product launches [38]. Group 5 - The Chinese government is actively supporting the innovation drug sector through various policies aimed at enhancing accessibility and encouraging high-quality innovation [16][18]. - The proportion of medical insurance spending on innovative drugs is steadily increasing, with 149 innovative drugs included in the insurance coverage over the past seven years [90][94]. - The average price reduction for innovative drugs during negotiations with the national medical insurance has been around 60%, with some drugs seeing reductions as high as 94% [88][94].

Group 1 - The core viewpoint of the report highlights that the pharmaceutical industry in China is experiencing a reversal in 2025, driven by innovative drugs, with significant benefits observed in the CXO and upstream supply chain sectors, particularly in the Hong Kong stock market where innovative drugs have seen a rise of over 80% year-to-date [1][4] - The report emphasizes that the core catalyst for innovative drugs comes from policy support and the realization of business development (BD) opportunities abroad, with notable transactions exceeding 1 billion USD, validating the international competitiveness of Chinese innovative drugs [1][2] - A significant reform in the payment sector is underway, with the introduction of a dual-track system for medical insurance, allowing for the inclusion of high-value innovative drugs in commercial insurance, addressing the gap in coverage for expensive treatments [1][2] Group 2 - The report indicates a rapid growth trend in the number of license-out transactions by Chinese pharmaceutical companies, with total upfront payments reaching 6.298 billion USD, a 53% year-on-year increase, and total transaction amounts reaching 118.862 billion USD, a 125% increase [2] - Looking ahead to 2026, the report suggests a shift from "BD-driven" to "data-driven" investment in innovative drugs, emphasizing the importance of clinical data validation and commercial capabilities for revenue growth [2] - Recommended stocks for investment include Heng Rui Medicine, Kelun-Biotech, and Teva Biopharmaceuticals, among others, while companies like Kangfang Biotech and Innovent Biologics are suggested for further attention [2][3] Group 3 - The overall profitability of the pharmaceutical sector remains stable, with a gradual improvement in the profitability of the pharmaceutical manufacturing industry, despite a slight decline in revenue growth [11][15] - The report notes a significant divergence within the industry, with the medical services sector performing well, while the profits of the biopharmaceutical sector have seen a substantial decline [28][29] - The report highlights that the medical insurance fund's income and expenditure growth rates are stabilizing, indicating a long-term trend towards cost control in medical insurance, which is essential for the sustainable development of the innovative drug industry [31][36]

Core Insights - The report from CMB International indicates a leading rating for the mainland pharmaceutical industry, following the National Healthcare Security Administration's announcement of the results from the 2025 Innovative Drug High-Quality Development Conference [1] Group 1: Industry Developments - The recent negotiations for the medical insurance and commercial insurance innovative drug catalog have resulted in many innovative pharmaceutical companies covered by CMB International having products newly included or successfully renewed in the insurance coverage [1] - Companies such as Heng Rui Medicine (600276), Innovent Biologics (01801), CanSino Biologics (09926), and China National Pharmaceutical Group (01177) have more than five products that received new coverage or new indications [1] Group 2: Market Outlook - The inclusion of more new drugs in the catalog is expected to enhance clinical medication levels and improve the overall R&D return rates in the innovative drug industry [1] - The introduction of commercial insurance funds is anticipated to provide significant incremental funding for innovative drug payments, paving the way for a diversified payment system alongside basic medical insurance [1] Group 3: Future Growth Potential - CMB International is optimistic about the sales growth potential of newly included products/indications in 2026, particularly for potential blockbuster products from companies like CanSino Biologics [1] - The report emphasizes the importance of monitoring the actual execution and payment situations of the first batch of commercial insurance catalog, as well as the dynamic adjustments in the list and pricing, and the long-term development opportunities arising from real-world data accumulation [1]

Core Viewpoint - The integration of basic medical insurance and commercial health insurance is driving innovation in drug research and application in China, with significant advancements in the pharmaceutical industry over the past decade [1] Group 1: Drug Development and Market Trends - From January to October, China has authorized over 700 innovative drugs overseas, with a total value exceeding $100 billion [1] - The 2025 National Medical Insurance Drug List includes 114 new drugs, of which 50 are first-class innovative drugs, showing an overall success rate of 88%, up from 76% in 2024 [1] - The first version of the commercial health insurance innovative drug list includes 19 drugs, covering treatments for CAR-T, neuroblastoma, Gaucher disease, and Alzheimer's disease [1][4] Group 2: Characteristics of the Commercial Health Insurance Drug List - The commercial health insurance drug list emphasizes support for innovation, including advanced therapies such as CAR-T, TCE therapy, and bispecific antibodies [4] - It addresses key areas of concern, including drugs for Alzheimer's disease and rare diseases prevalent in children, reflecting the aging population trend [4] - The list delineates the boundary between basic medical insurance and commercial insurance, with basic insurance focusing on safe and effective drugs, while commercial insurance prioritizes innovative and cutting-edge medications [4] Group 3: Collaboration and Future Outlook - Companies like 合源生物科技股份有限公司 are actively collaborating with the National Medical Insurance Bureau and commercial health insurance providers to implement related plans and enhance patient awareness of health insurance [5][6] - The commercial health insurance innovative drug list is seen as a significant step in supporting the development of innovative drugs and establishing a multi-tiered medical payment system [6] - The 2025 National Medical Insurance Drug List includes drugs that fill gaps in basic insurance coverage for major diseases and rare conditions, increasing the total number of drugs to 3,253 [6]

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The development of commercial health insurance is supported by favorable policies, with significant potential for capital inflow. Since 2009, policies have continuously supported the establishment of a multi-level medical security system and the development of commercial health insurance. The sharing of medical insurance data with commercial insurance companies is entering a practical phase, which is expected to improve the insurance landscape [2][28] - The commercial health insurance sector is projected to reach a compensation scale of approximately 471.57 billion yuan by 2030 under neutral expectations, indicating substantial potential for the medical industry [31][32] Summary by Sections Part 1: Commercial Health Insurance is Flourishing, Compensation Growth is Expected - The demand side emphasizes the impact of premium pricing and the insurance needs of patients with pre-existing conditions and the elderly. The increase in disposable income and policies allowing the use of personal medical insurance accounts for purchasing health insurance are expected to enhance insurance uptake [11][12][29] - The supply side highlights the importance of product design in health management, special drug coverage, and deductible settings. Enhancements in these areas can attract more policyholders and improve profitability [20][21][28] Part 2: Current Situation: Insufficient Motivation for Innovative Drug and Device Use - The DRG payment system has reduced the motivation for hospitals to use innovative drugs and devices, necessitating the exploration of alternative payment sources. High-level hospitals face greater pressure under the DRG system, which may hinder the adoption of innovative treatments [35][39] Part 3: Commercial Insurance Development Benefits Innovative Drugs and DTP Pharmacies - The commercial health insurance sector is increasingly covering innovative drugs, with payments rising from 1.1 billion yuan in 2020 to 2.2 billion yuan in 2023, reflecting a compound annual growth rate of 27.8%. The penetration rate for commercial health insurance in the innovative drug market remains low, indicating significant room for growth [67][68] - DTP pharmacies are emerging as a crucial channel for the distribution of innovative drugs, providing a pathway for patients to access high-value medications outside of traditional hospital settings [76][80] Part 4: Innovative Devices May Benefit from Commercial Insurance Development - Innovative medical devices, particularly those not fully covered by insurance, are expected to benefit from commercial insurance. The report suggests that high-value medical devices and certain surgical procedures may gain traction in the commercial insurance market [4][81] Part 5: Investment Recommendations - The report recommends focusing on companies with rich pipelines in innovative drugs, such as Heng Rui Medicine and BeiGene, as well as DTP pharmacies and TPA (Third Party Administrator) companies that are well-positioned to benefit from the growth of commercial health insurance [4][81]

Core Insights - The report from CICC highlights a clear trend of innovation going global in the biopharmaceutical sector, with a shift from "importing and imitating" to "innovating and exporting" in China's pharmaceutical industry [1] Group 1: Industry Trends - The pharmaceutical review reform continues to yield benefits, supported by domestic engineering talent, abundant clinical resources, and favorable policies, marking the entry of China's innovative drug industry into its 2.0 era [1] - The internal demand, which has been weak, is gradually improving, and breakthroughs in commercial insurance are alleviating payment conflicts [1] - The medical anti-corruption campaign that began in 2023 is expected to transition into normalization in 2024, with a gradual easing of its impact on the industry by 2025 [1] Group 2: Policy and Market Dynamics - Policies aimed at reducing internal competition are reflected in the pharmaceutical procurement sector, where the price anchors for the first batch of generic drug procurements have loosened, moving away from a sole focus on low prices [1] - The exploration of a diversified payment system is ongoing, with increasing calls for commercial insurance [1] - The impact of policy shocks on regions is easing, and while internal demand remains weak in the short term, there are signs of improvement [1] Group 3: Investment Strategy - The "dumbbell strategy" for 2026 remains applicable, emphasizing a combination of technological advancement and traditional defensive measures [1] - There is optimism regarding the progressive attributes of medical technology, with notable developments in AI and healthcare alongside breakthroughs in innovative drugs and internationalization [1]

Group 1 - The core viewpoint of the article highlights the introduction of several high-value "star drugs" in the commercial health insurance innovative drug directory, which is expected to create new payment channels and benefit a broader patient population [1][2] - The National Healthcare Security Administration (NHSA) has initiated the adjustment of the commercial health insurance innovative drug directory, marking a significant step towards a multi-layered and balanced payment structure in the healthcare industry [1][2] - According to Frost & Sullivan, the share of commercial health insurance payments is projected to reach 16.3% by 2030, more than doubling from 2024, indicating a growing trend in the market [2] Group 2 - The construction of a diversified medical payment system faces challenges, including fragmented reimbursement rules and payment proportions across different payment methods, which complicates the payment process [2][3] - The "Yima Direct Payment" platform by Meixin Health exemplifies how platform companies are effectively addressing these challenges by integrating various payment solutions and streamlining complex claims processes [3] - The importance of ensuring that innovative drugs are accessible post-launch, including prescription transmission and direct payment capabilities, is emphasized as a critical factor for commercial insurance [2][3]